GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (NAS:IMUX) » Definitions » Cost of Goods Sold

Immunic (Immunic) Cost of Goods Sold : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Immunic Cost of Goods Sold?

Immunic's cost of goods sold for the three months ended in Mar. 2024 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Immunic's Gross Margin % for the three months ended in Mar. 2024 was %.

Cost of Goods Sold is also directly linked to Inventory Turnover.


Immunic Cost of Goods Sold Historical Data

The historical data trend for Immunic's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Cost of Goods Sold Chart

Immunic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immunic Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immunic Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunic  (NAS:IMUX) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Immunic's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Immunic's Inventory Turnover for the three months ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Immunic Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Immunic's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunic (Immunic) Business Description

Traded in Other Exchanges
Address
1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Executives
Glenn Whaley officer: PAO and Controller C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Richard Alan Rudick director 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK NY 10036
Joerg Neermann director IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Daniel Vitt director, officer: CEO, President IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Monika Maria Toernsen director ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Duane Nash director C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andreas Muehler officer: Chief Medical Officer 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK CITY NY 10036
Manfred Groeppel officer: Chief Operating Officer IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Barclay A Phillips director C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Tamar D Howson director
Sanjay S Patel officer: Chief Financial Officer 10 N. PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Claudio Nessi 10 percent owner C/O NEOMED, 7 PLACE DU MOLARD, 1204 GENEVA V8 1204
Anne-mari Paster 10 percent owner C/O OMEGA FUND MANAGEMENT, LLC, 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Lsp V Cooperatieve U.a. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV